About Rivus Clinical Research
Driven by the commitment to scientific excellence and patient safety, our efforts to advance medical knowledge and bring transformative therapies to the global community.
The healthcare landscape is rapidly changing. The time is now for a thoughtful, innovative responses to those changes.
We do not allow fear of the unknown to prevent what may be possible. With this mindset, we move forward with a total commitment to marrying the best scientific insights with the most thoughtful care.
A passion for informed, total wellness brings us together, and it unifies our efforts on behalf of every patient.
DR. LANE PEYTON, MD
Dr. Peyton is a board certified psychiatrist and psychotherapist who works with adults, adolescents, and the elderly in a psychotherapy-based clinic in Northwest Oklahoma City. As a psychotherapist, he offers various modalities of individual psychotherapy, to include psychodynamic, interpersonal, cognitive-behavioral, and supportive modalities, as well as couples therapy and family therapy, designed to address the various needs of patients and their families. As a psychiatrist, he prescribes mental health or “psychotropic†medications to include antidepressant medications, anti-anxiety or “anxiolytic†medications, mood stabilizers, antipsychotic medications, and other medications when safe and indicated. As a medical doctor (M.D.), he is trained to consider the psychological implications of various medical conditions to include Dementia, Depression, Schizophrenia, Addiction, Pain, as well as the psychological impact of the many medications prescribed to treat these conditions.
DR. DAVID SHORTS
PsyD, Director of Voyager, Psychedelic Lead Therapist
Dr. David Short is a Licensed Clinical Psychologist with over 12 years of experience. He holds a Doctorate in Clinical Psychology from the California School of Professional Psychology and is a licensed psychologist in the state of Oklahoma. David is excited about the potential for psychedelics to transform the treatment of mental illness and facilitate psychological growth. He has completed training in ketamine, psilocybin, and MDMA-assisted psychotherapy protocols. Currently, he utilizes ketamine-assisted psychotherapy in his clinical practice and serves as the lead therapist in a research trial examining the efficacy of psilocybin on treatment-resistant depression. Outside of his professional life, David enjoys spending time in the mountains or by the ocean, where he feels most at home.